532 related articles for article (PubMed ID: 17259955)
1. Drug interaction studies: study design, data analysis, and implications for dosing and labeling.
Huang SM; Temple R; Throckmorton DC; Lesko LJ
Clin Pharmacol Ther; 2007 Feb; 81(2):298-304. PubMed ID: 17259955
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic protein-drug interactions and implications for drug development.
Huang SM; Zhao H; Lee JI; Reynolds K; Zhang L; Temple R; Lesko LJ
Clin Pharmacol Ther; 2010 Apr; 87(4):497-503. PubMed ID: 20200513
[TBL] [Abstract][Full Text] [Related]
3. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.
Huang SM; Strong JM; Zhang L; Reynolds KS; Nallani S; Temple R; Abraham S; Habet SA; Baweja RK; Burckart GJ; Chung S; Colangelo P; Frucht D; Green MD; Hepp P; Karnaukhova E; Ko HS; Lee JI; Marroum PJ; Norden JM; Qiu W; Rahman A; Sobel S; Stifano T; Thummel K; Wei XX; Yasuda S; Zheng JH; Zhao H; Lesko LJ
J Clin Pharmacol; 2008 Jun; 48(6):662-70. PubMed ID: 18378963
[TBL] [Abstract][Full Text] [Related]
4. International Conference on Harmonisation; choice of control group and related issues in clinical trials; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2001 May; 66(93):24390-1. PubMed ID: 12356096
[TBL] [Abstract][Full Text] [Related]
5. International conference on harmonisation; guidance on statistical principles for clinical trials; availability--FDA. Notice.
Fed Regist; 1998 Sep; 63(179):49583-98. PubMed ID: 10185190
[TBL] [Abstract][Full Text] [Related]
6. The Investigators' Brochure: a comparison of the draft international conference on harmonisation guideline with current Food and Drug Administration requirements.
Cocchetto DM
Qual Assur; 1995 Dec; 4(4):240-6. PubMed ID: 8890349
[TBL] [Abstract][Full Text] [Related]
7. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial design issues in schizophrenic research.
Casey DE
J Clin Psychiatry; 2001; 62 Suppl 9():17-20; discussion 21-2. PubMed ID: 11379826
[TBL] [Abstract][Full Text] [Related]
9. Pharmacometrics at FDA: evolution and impact on decisions.
Powell JR; Gobburu JV
Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
[TBL] [Abstract][Full Text] [Related]
10. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.
Chuang-Stein C; Beltangady M
J Biopharm Stat; 2010 Nov; 20(6):1143-9. PubMed ID: 21058110
[TBL] [Abstract][Full Text] [Related]
11. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease.
Zhang L; Xu N; Xiao S; Arya V; Zhao P; Lesko LJ; Huang SM
J Clin Pharmacol; 2012 Jan; 52(1 Suppl):79S-90S. PubMed ID: 22232757
[TBL] [Abstract][Full Text] [Related]
12. International Conference on Harmonisation; Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2010 Jan; 75(13):3471-2. PubMed ID: 20349552
[TBL] [Abstract][Full Text] [Related]
13. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2009 Apr; 74(66):15990-1. PubMed ID: 19507321
[TBL] [Abstract][Full Text] [Related]
14. International Conference on Harmonisation; guidance on S7A safety pharmacology studies for human pharmaceuticals; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2001 Jul; 66(135):36791-2. PubMed ID: 12356097
[TBL] [Abstract][Full Text] [Related]
15. Policy developments in regulatory approval.
Temple R
Stat Med; 2002 Oct; 21(19):2939-48. PubMed ID: 12325110
[TBL] [Abstract][Full Text] [Related]
16. Viewpoints on the FDA draft adaptive designs guidance from the PhRMA working group.
Gallo P; Anderson K; Chuang-Stein C; Dragalin V; Gaydos B; Krams M; Pinheiro J
J Biopharm Stat; 2010 Nov; 20(6):1115-24. PubMed ID: 21058107
[TBL] [Abstract][Full Text] [Related]
17. FDA perspective on clinical trial design for cardiovascular devices.
Chen E; Sapirstein W; Ahn C; Swain J; Zuckerman B
Ann Thorac Surg; 2006 Sep; 82(3):773-5. PubMed ID: 16928481
[No Abstract] [Full Text] [Related]
18. GCP data quality for early clinical development.
Rock EP; Molloy VJ; Humphrey JS
Clin Cancer Res; 2010 Mar; 16(6):1756-63. PubMed ID: 20215550
[TBL] [Abstract][Full Text] [Related]
19. Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels.
Basch E
Value Health; 2012 May; 15(3):401-3. PubMed ID: 22583448
[No Abstract] [Full Text] [Related]
20. International Conference on Harmonisation; guidance on ethnic factors in the acceptability of foreign clinical data; availability--FDA. Notice.
Fed Regist; 1998 Jun; 63(111):31790-6. PubMed ID: 10180134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
